WIN Symposium to take place in Paris from June 28-29

NewsGuard 100/100 Score

On June 28 and 29, academic thought leaders and high-ranking officers from pharma, biotech and information technology companies will gather in Paris at the 4th WIN Symposium to present and discuss breakthroughs that will bring personalized cancer medicine to the next phase. The Symposium will address new ways to advance individualized cancer therapy by applying new technologies, including targeted therapeutics and diagnostic biomarkers, and by designing and conducting innovative clinical trials in oncology. The program will include the first-ever disclosure of new technologies that are able to predict the efficacy of therapeutics for the treatment of cancer patients on an individual basis.

Both sides - academia and industry - will equally contribute to the presentations and discussions. Experts participating from the academic side include: James Doroshow (NCI), Ronald DePinho (USA), John Mendelsohn (USA); Alexander Eggermont (France); William Dalton (USA), Richard L. Schilsky (USA), Leroy Hood (Canada), and others. Industry will be represented by among others Brett Davis (Oracle Corporation), Richard Gaynor (Eli Lilly and Company), Steven Averbuch (Bristol-Myers Squibb), Nick Botwood (AstraZeneca), Paolo Paoletti (GlaxoSmithKline), and Christopher Viehbacher (Sanofi).

The program has received endorsements by ASCO, ESMO, UICC and INCa. It has been recognized as one of educational value for medical specialists, which is reflected by the awarding of 12 European CME credits and 17 ESMO MORA credits.

The 4th WIN Symposium is the next annual of the WIN Consortium (www.winconsortium.org), a joint initiative of Cancer Institute Gustave Roussy, France, and The University of Texas - MD Anderson Cancer Center, USA, which brings together 22 cancer centers from around the world and technology partners, including Agilent Technologies, GE Healthcare, Life Technologies, and Foundation Medicine.

Advance registration for the symposium at reduced rates remains open until June 24 via the WIN Consortium website. On-site registration in Paris will be open as of June 27.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study links air pollution to increased colorectal cancer risk through DNA changes